LUPIN
Large Cap BSE: 500257 NSE: LUPIN
₹654.8
-15.4 (-2.3%)
  • Advice
  • Hold
As on 30 September, 2022 | 01:58

Lupin Share Price

Lupin Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in LUPIN

Start SIP

Lupin Share Returns

  • Over 1 Month -1.08%
  • Over 3 Month 5.5%
  • Over 6 Month -14.01%
  • Over 1 Year -30.9%

Lupin Key Statistics

P/E Ratio -13.8
PEG Ratio 0.1
Market Cap Cr 29,772
Price to Book Ratio 2.4
EPS -4.9
Dividend 0.6
Relative Strength Index 47.85
Money Flow Index 36.05
MACD Signal -1
Average True Range 19.04

Lupin Investment Rating

  • Master Rating:
  • Lupin (Nse) has an operating revenue of Rs. 15,879.13 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of -8% needs improvement, ROE of -12% is poor and needs improvement. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 7 which is a FAIR score but needs to improve its earnings, a RS Rating of 18 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 124 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Lupin Financials
IndicatorJun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 2,6842,5042,6632,7993,3142,516
Operating Expenses Qtr Cr 2,4442,3542,5244,2692,3492,091
Operating Profit Qtr Cr 289501208-1,399965425
Depreciation Qtr Cr 130131128130125125
Interest Qtr Cr 202516181512
Tax Qtr Cr 28397-430-14320437
Net Profit Qtr Cr 117-36530-1,329646316

Lupin Technicals

EMA & SMA

Current Price
654.8
-15.4 (-2.3%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 659.94
  • 50 Day
  • 659.62
  • 100 Day
  • 675.31
  • 200 Day
  • 733.22
  • 20 Day
  • 659.44
  • 50 Day
  • 660.51
  • 100 Day
  • 645.98
  • 200 Day
  • 732.86

Lupin Resistance and Support

PIVOT
₹662.99
Resistance
First Resistance 679.62
Second Resistance 689.04
Third Resistance 705.67
RSI 47.85
MFI 36.05
MACD Single Line -1
MACD -1.19
Support
First Resistance 653.57
Second Resistance 636.94
Third Resistance 627.52

Lupin Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 4,484,112 256,670,571 57.24
Week 1,623,868 71,645,074 44.12
1 Month 1,016,871 39,993,527 39.33
6 Month 1,289,751 44,044,991 34.15

Lupin Result Highlights

Lupin Synopsis

NSE-Medical-Generic Drugs

Lupin Ltd. is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 11771.67 Cr. and Equity Capital is Rs. 90.90 Cr. for the Year ended 31/03/2022. Lupin Ltd. is a Public Limited Listed company incorporated on 01/03/1983 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24100MH1983PLC029442 and registration number is 029442.
Market Cap 29,772
Sales 11,190
Shares in Float 24.10
No of funds 557
Yield 0.61
Book Value 1.64
U/D Vol ratio 1.3
LTDebt / Equity
Alpha -0.13
Beta 0.87

Lupin

Owner NameJun-22Mar-22Dec-21Sep-21
Promoters 47.1%46.78%46.81%
Mutual Funds 15.86%15.72%13.26%
Insurance Companies 10.82%10.98%11.36%
Foreign Portfolio Investors 14.27%14.65%15.28%
Financial Institutions/ Banks 0.14%0.14%0.14%
Individual Investors 8.59%8.53%9.98%
Others 3.22%3.2%3.17%

Lupin Management

Name Designation
Mrs. Manju D Gupta Chairman
Dr. Kamal K Sharma Vice Chairman
Mr. Nilesh D Gupta Managing Director
Ms. Vinita Gupta Executive Director & CEO
Mr. Ramesh Swaminathan Executive Director & Global CFO
Mr. Jean-Luc Belingard Independent Director
Ms. Christine Mundkur Independent Director
Mr. K B S Anand Independent Director
Dr. Punita Kumar-Sinha Independent Director
Mr. Mark D McDade Independent Director

Lupin Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Lupin Corporate Action

Date Purpose Remarks
2022-08-03 Quarterly Results
2022-05-18 Audited Results & Final Dividend
2022-02-03 Quarterly Results
2021-10-27 Quarterly Results
2021-08-10 Quarterly Results
Date Purpose Remarks
2022-07-15 FINAL Rs.4.00 per share(200%)Final Dividend
2021-07-28 FINAL Rs.6.50 per share(325%)Final Dividend

Lupin MF Shareholding

Name Amount(cr)
HDFC Balanced Advantage Fund Growth 48055
ICICI Prudential Balanced Advantage Fund Growth 42930
Kotak Flexicap Fund Growth 37435
ICICI Prudential Bluechip Fund Growth 33739
HDFC Flexi Cap Fund Growth 30473

About Company

Dr Desh Bandhu Gupta founded in 1968 in Mumbai, Lupin is one of the top pharmaceutical manufacturers. It has 15 manufacturing facilities, 6 API facilities, 7 research facilities and more than 23 global offices. 

Lupin ranks 6th by sales in India. It ranks #2 in respiratory and #3 in cardiac and anti-diabetes segments. While the market growth in the chronic disease portfolio has been 11% in the last five years, Lupin has been growing at 14% YoY.
 
Over the last 4 years, it has invested over $1bn in R&D in areas of biosimilars, complex generics, long-acting complex injectables, inhalation and speciality portfolio. 

Business Verticals

1. Global Formulations
2. Active Pharmaceuticals Ingredients (API)
3. Biotech
4. Specialty Business
5. Over The Counter (OTC)
6. Biosimilars
7. Generic drugs


Company History

Lupin commenced operations in 1968 on Gudi Padwa as a vitamins manufacturer. It is named after the Lupin flower, which can tolerate infertile soils and poor climatic conditions. Its first major order was iron and folic acid tablets for mother and child healthcare programmes backed by the Government of India.

Today, it develops branded and generic formulations, APIs, and biotechnology products and sells across 100 markets, including the US, Japan, and Mexico. Lupin is one of the world's largest manufacturers of TB drugs. The company has a significant market share across multiple therapy areas such as Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System, Gastro-Intestinal, Anti-Infective, and Non-Steroidal Anti-Inflammatory Drugs. 
 

Milestones
 

1968 - Dr Desh Bandhu Gupta started Lupin.

1972 - Lupin Laboratories Pvt. Ltd. was incorporated.

1979 - They commissioned the first formulation plant and R&D Centre at Aurangabad.

1981 - They started the production of Ethambutol.

1987 - Cephalexin plant at Mandideep and 7 ADCA plants at Ankleshwar went on stream.

1988 - Commenced Lupin Human Welfare and Research Foundation (LHWRF).

1989 - Started Lupin Chemicals (Thailand) Ltd. Received U.S. FDA approvals for the Ankleshwar and Mandideep plants.

1991 - Initiated the production of injectable Cephalosporin at Mandideep.

1992 - Commenced a sterile fermentation plant for injectable Cephalosporins at Mandideep.

1993 - Lupin Laboratories Ltd. and Lupin Chemicals Ltd. floated their IPOs.

1997 - Three facilities received U.S. FDA approvals.

2000 - Another plant received US FDA approval.

2001 - Lupin Laboratories Ltd. amalgamated with Lupin Chemicals Ltd. to form Lupin Ltd. and established the Lupin Research Park in Pune. Lupin became the only Asian pharmaceutical company to receive U.S. FDA approvals for its sterile Cephalosporin facility.

2002 - ORG-Marg rated Rablet as the 2nd best launch of 2002-03; patent filings exceed 100.

2003 - Received WHO approval for the formulation plant at Aurangabad. Lupin Pharmaceuticals Inc. USA is formed.

2004 - Started U.S. brands’ business with the launch of Suprax.

2005 - Commenced its generics business in the U.S. Implemented ESOP.

2006 - Announced the issue of FCCBs, with a listing on the Singapore Stock Exchange.

2007 - Acquired Kyowa Pharmaceuticals of Japan; and Rubamin Laboratories of India.

2008 - Acquired Hormosan Pharma GmbH, Germany. Also acquired stakes in Generic. Health Pty Ltd., Australia and Pharma Dynamics, South Africa.

2009 - Acquired majority stake in Multi-Care Pharmaceuticals Inc., Philippines.

2010 - Lupin ranked the 5th largest generic player in the U.S.

2011 - Began commercial production at the new oral solid dosage facility at Pithampur; acquired I’rom Pharmaceuticals, Japan and of worldwide rights for the Goanna Brand.

2012 - Lupin enters Nifty 50.

2014 - Acquired Nanomi BV of the Netherlands and Laboratorios Grin S.A. De C.V., Mexico.

2015 - Acquired Pharma Dynamics, South Africa, Medquimica Industria, Brazil; Specialty product portfolio of Temmler Pharma GMBH & Co., Germany.

2016 - Acquired Gavis Pharma, U.S; launched a new plant at Tottori, Japan.

2017 - Launched Softovac in the OTC segment; acquired Symbiomix Therapeutics, U.S.

2019 - Divestment of Kyowa Pharmaceutical Industry Co. Ltd., in Osaka.

2020 - Launched Etanercept Biosimilar in EU and gProAir, a key inhalation product.

Lupin FAQs

What is Share Price of Lupin ?

Lupin share price is ₹654 As on 30 September, 2022 | 01:44

What is the Market Cap of Lupin ?

The Market Cap of Lupin is ₹29772.1 Cr As on 30 September, 2022 | 01:44

What is the P/E ratio of Lupin ?

The P/E ratio of Lupin is -13.8 As on 30 September, 2022 | 01:44

What is the PB ratio of Lupin ?

The PB ratio of Lupin is 2.4 As on 30 September, 2022 | 01:44

What were the company's reported sales and net income in 2022?

For the year ending March 2022, Lupin reported a consolidated sales figure of INR 16,405 crores and a net loss of INR 1,528 crores. Its standalone sales and net loss for the same period stood at INR 11,772 crores and 189 crores respectively.

What is the future of Lupin Limited's shares?

Lupin’s future looks slightly bleak. The company has shown a negative net profit growth rate of 2.18% and revenue growth of 3.10% for the past 3 years. However, the company is virtually debt-free.

How to buy Lupin’s shares?

You can easily buy and sell the company's shares by creating a Demat account with 5Paisa.
 

Q1FY23